NeoGenomics (NEO)

• Market cap: $973M
• 1 day: -4.33%
• 5 days: -6.48%
• 1 month: -15.43%
• 3 months: -25.74%
• 6 months: -60.12%
• Year to date: -57.13%
• 1 year: -47.32%
• 5 years: -74.87%
• 10 years: 21.48%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Employees: 2,200

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

508% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $1.78M

19% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 37

2.63% more ownership

Funds ownership: 95.52% [Q4 2024] → 98.15% (+2.63%) [Q1 2025]

1% more funds holding

Funds holding: 250 [Q4 2024] → 252 (+2) [Q1 2025]

19% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 89

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]

41% less capital invested

Capital invested by funds: $2.02B [Q4 2024] → $1.2B (-$822M) [Q1 2025]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8.50 20% upside
• Avg. target: $9.90 40% upside
• High target: $12 70% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Piper Sandler David Westenberg	70% upside $12	Overweight Maintained	6 May 2025
Morgan Stanley Tejas Savant	41% upside $10	Equal-Weight Maintained	1 May 2025
Goldman Sachs Matthew Sykes	41% upside $10	Buy Maintained	30 Apr 2025
Leerink Partners Puneet Souda	27% upside $9	Market Perform Downgraded	30 Apr 2025
Needham Mike Matson	20% upside $8.50	Buy Maintained	29 Apr 2025